...
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers.
【24h】

Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers.

机译:舒洛地昔治疗静脉曲张性溃疡的随机,双盲,多中心,安慰剂对照研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Sulodexide, a highly purified glycosaminoglycan, was investigated for treatment of venous leg ulcers. Patients (n = 235) undergoing local treatment including wound care and compression bandaging, were randomised to receive either sulodexide or matching placebo for three months. Primary study endpoint was complete ulcer healing after 2 months; secondary endpoints were ulcer healing at 3 months and the time-course changes of ulcer areas. The proportion of patients with complete ulcer healing was higher with sulodexide at 2 months (p = 0.018) and 3 months. The "number needed to treat" to obtain one additional patient healed with sulodexide was 7 at 2 months and 5 at 3 months. The changes in ulcer surface area with time were significant for sulodexide only (p = 0.004). Fibrinogen significantly decreased in sulodexide patients (p = 0.006). In conclusion, sulodexide associated with local treatment proved to be effective and well tolerated in the management of venous leg ulcers.
机译:Sulodexide是一种高度纯化的糖胺聚糖,用于治疗下肢静脉溃疡。接受局部治疗(包括伤口护理和加压包扎)的患者(n = 235)被随机分配接受舒洛地昔或安慰剂三个月的治疗。主要研究终点是2个月后溃疡完全愈合;次要终点是3个月时溃疡愈合和溃疡区域随时间变化。在2个月(p = 0.018)和3个月时,使用舒洛地昔可完全治愈溃疡的患者比例更高。获得另外一名舒洛地昔治愈的患者的“需要治疗的数目”在2个月时为7,在3个月时为5。溃疡表面积随时间的变化仅对舒洛地昔有意义(p = 0.004)。 sulodexide患者的纤维蛋白原显着减少(p = 0.006)。总之,舒洛地特与局部治疗的结合被证明在治疗腿部静脉溃疡方面有效且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号